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Abstract 
Neonatal Abstinence Syndrome (NAS) is a condition in which an infant experiences 
withdrawal from uterine exposure to various substances such as caffeine, nicotine, 
amphetamines, THC, opioids, benzodiazepines, and other types of substances. Depending on the 
severity of the symptoms, these infants may experience a longer hospital stay and may need 
treatment and monitoring in the neonatal intensive care unit (NICU), resulting in an increase in 
healthcare costs. The objective of this project was to determine if targeted drug screening of 
newborns was effective in determining infants at risk of NAS based on a positive screening 
result. This study utilized a retrospective, cross-sectional electronic health record (EHR) review 
of infants born between September 1st, 2015 and September 1st, 2016 who met criteria for 
umbilical cord drug screening. Rates of umbilical cord drug screening and screening results were 
compared to risk factors associated with targeted drug screening criteria to determine which risk 
factor criteria were predictive of a positive umbilical cord drug screening result. The EHR 
records of 340 infants met criteria. Risk factors associated with targeted drug screening criteria 
were not significantly sensitive nor specific in predicting infants at risk of NAS based on positive 
drug screen results. In order to truly identify all infants at risk for withdrawal, universal 
screening is recommended. 
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Neonatal Abstinence Syndrome: Is Targeted Umbilical Cord Drug Screening Effective in 
Determining Risk of Withdrawal? 
 
Background 
Neonatal Abstinence Syndrome (NAS) is a growing health problem in the United 
States. “Between 2004 and 2014, the incidence of NAS in the United States increased from 1.5 
per 1000 hospital births to 8.0 per 1000 hospital births, a more than fivefold increase” 
(Winkelman, Villapiano, Kozhimannil, Davis, & Patrick, 2018). NAS is a condition in which an 
infant experiences withdrawal from uterine exposure to various substances such as caffeine, 
nicotine, amphetamines, THC, opioids, benzodiazepines, and other types of substances. 
Depending on the severity of the symptoms, these infants may experience a longer hospital stay 
and may require treatment and monitoring in the neonatal intensive care unit (NICU), resulting 
in an increase in healthcare costs. When comparing healthcare costs from 2004 to 2014 of infants 
with NAS covered by Medicaid, there was an annual increase in cost from $65.4 million in 2004 
to $462 million in 2014. Over this ten-year period, there was over $2 billion in additional costs 
for infants with a NAS diagnosis (Winkelman et al., 2018). NAS can lead to withdrawal 
symptoms within the first 12-72 hours of life that include central nervous system (CNS) 
disturbances, vasomotor dysregulation, gastrointestinal disturbances, and hyperirritability such as 
tremors, fever, tachypnea, excoriation, diaphoresis, high-pitched crying, lack of sleep, vomiting, 
diarrhea, and more severe symptoms such as seizures and respiratory distress (American College 
of Obstetricians and Gynecologist, 2017; McQueen & Murphy-Oikonen, 2016; Timpson, 
Killoran, Maranda, Picarillo, & Bloch-Salisbury, 2018). There are also long-term effects from 
NAS. Infants who developed NAS were at an increased risk for problems with their vision, 
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behavior, cognition, sleep, and ear infections as they matured (Maguire et al., 2016). There is 
also a strong association between substance abuse disorder and child maltreatment, with 40-56% 
of parents having abused or neglected their child when using substances (Maguire et al., 2016). 
In a study described by Maguire et al. (2016), the incidence of child abuse was doubled when a 
parent had a substance use disorder. NAS is a condition which not only affects an infant at birth, 
but also throughout their lifetime as these problems continue to develop.  
Determination of risk for NAS can be evaluated in a number of ways in regard to drug 
screening mothers and/or infants (Terplan & Minkoff, 2017). Drug screening can be performed 
on maternal or infant blood, urine, or hair as well as infant meconium, umbilical cord, or 
placenta (McQueen & Murphy-Oikonen, 2016; Price, Collier, & Wright, 2018). Screening can 
be selective, where drug testing is performed only if certain criteria are met. This may include 
validated questionnaires provided to the mother or may be based on admission of a history of 
substance use or abuse, placental abruption, precipitous labor, limited or no prenatal care, or 
behavior suggestive of substance use in the mother or withdrawal in the infant. Drug screening 
can also be universal, where all mothers or infants are chosen for drug screening. According to 
Terplan and Minkoff (2017), selective drug screening is more cost-effective because it allows the 
physician to narrow down those mothers who are at greatest risk of substance abuse, which 
improves efficiency and specificity. However, the disadvantage with selective drug screening is 
the decision to test may be based on bias or judgment and mothers and infants can be missed. In 
a study described by Terplan and Minkoff (2017), black women and poor women were more 
likely than others to be reported to social services, and infants of black women were more likely 
to be drug screened. “Universal testing avoids the risk of implicit bias and has the advantage of 
simplicity” (Terplan & Minkoff, 2017, p. 165). This also avoids relying on a woman’s honesty in 
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her substance abuse history to decide whether an infant is screened and monitored for 
withdrawal. Often, women are scared to admit information about their drug use history due to 
fear of being reported to social services or having legal action taken against them (Truog, 2015).  
In the state of Kentucky, where this research was conducted, the incidence of NAS has 
increased thirty-sevenfold from 2000-2013, with 0.4 cases per 1000 live births in 2000 and 15.0 
cases per 1000 live births in 2013 (National Institute on Drug Abuse, 2018). When looking at the 
incidence of NAS across the 28 states included in an analysis by the National Institute on Drug 
Abuse (2018), the overall United States average was 6.0 cases per 1000 live births. In an analysis 
by the Kentucky Department for Public Health (2016), the most common substances used by 
mothers during pregnancy were buprenorphine (58.4%), other opiates (35.2%), THC (22.8%), 
heroin (20.4%), amphetamines (14.4%), and benzodiazepines (14.2%). In this same report, the 
Kentucky Department for Public Health (2016) stated that outcomes for NAS included child 
fatalities due to unsafe sleep habits as well as nonaccidental head trauma. “Because babies with 
NAS can have irritability and feeding problems for months after discharge, they are likely to be 
at higher risk for these deaths” (Kentucky Department for Public Health, 2016, p. 11). With the 
continued rise in NAS diagnoses due to substance abuse in pregnancy in the United States and 
especially the commonwealth of Kentucky, it is imperative that a plan be made to identify which 
infants are most at risk of withdrawal.  
The goal of targeted drug screening of newborns is to identify newborns at risk of NAS 
by using risk factors often associated with maternal substance use. Early identification of infants 
at greatest risk of NAS can help determine infants who would benefit from early 
intervention/treatment. The objective of this project was to determine if targeted drug screening 
of newborns was effective in determining infants at risk of NAS. An additional aim was to 
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compare Finnegan scores of infants who were positive to those who were negative to determine 
the significance of Finnegan scoring in assessing signs of withdrawal. This project sought to 
compare positive drug screening results to the associated selective drug screening criteria in 
order to determine which screening criteria were most predictive of a positive result. 
Theoretical Framework 
 The theoretical framework chosen for this project was the John Hopkins Nursing 
Evidence-Based Practice (JHNEBP) Model, which uses a three-step process to provide and apply 
the latest and best research to nursing practice and patient care (John Hopkins University & 
Medicine, 2020). The three steps in this process are called PET: practice question, evidence, and 
translation. The first step in this model is presenting a practice question. The purpose of the 
practice question is to present the problem and find a focused and specific question that can 
guide what kind of study or evidence is needed to move forward. For this project, the practice 
question was: What is the best way to identify which infants are at risk of NAS? The next step in 
the JHNEBP Model is to search for the evidence and resources that can answer the practice 
question. By doing a thorough literature review, gaps in literature can be found and the practice 
question can be shaped to find the best type of study that is needed. For this project, the literature 
review revealed gaps in the research comparing targeted screening protocols to universal 
screening protocols at the same facility as well as identifying which targeted drug screening 
criteria were the most accurate in determining a positive result. The last step in the JHNEBP 
Model is translation, which uses the practice question and literature review to decide on what 
type of study to perform (John Hopkins University & Medicine, 2020). For this project, there 
were two different pathways to take when considering the practice question. When considering 
the gap in literature where targeted screening and universal screening had not been performed 
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and compared at the same facility, the first translation was to do a prospective study. This study 
would have consisted of implementing a universal screening protocol at a facility that already did 
risk-based screening, and then comparing the additional infants that were found to be at risk of 
NAS. The second translation was to perform a retrospective medical record review where risk-
based criteria were compared to the number of positive results in order to determine the 
sensitivity of risk-based screening. Due to the limitations in funding for universal screening and 
the need for informed consent from every parent, a retrospective literature review was chosen to 
determine the efficacy of a targeted screening protocol. The JHNEBP Model provided a straight 
forward straightforward approach to identifying the best study for this practice question and 
ensured that the latest research would be used to support this project (John Hopkins University & 
Medicine, 2020). 
Review of Literature 
The studies included in this literature review demonstrated a variety of information 
supporting the use of umbilical cord drug screening and early identification of infant’s at risk of 
withdrawal. One study utilized a systemic literature review, ten studies utilized a cohort analysis, 
one utilized a comparison study, one a cross-sectional study, and three studies utilized a survey 
(see Appendix A). Of the sixteen studies retrieved for this review, five examined hospital 
practices and protocols regarding drug-screening criteria and efficacy of drug testing (Bogen et 
al., 2017; Miller et al., 2014; Murphy-Oikonen et al., 2010; Wexelblatt et al., 2015; Wood et al., 
2017), four examined whether umbilical cord screening and meconium screening was equivalent 
(Colby, 2017; Colby et al., 2019; Labardee et al., 2017; Palmer et al., 2017), and four examined 
the prevalence of maternal substance abuse (Buchi et al., 2013; Kreshak et al., 2016; Lange et al., 
2016; Schauberger et al., 2014). Of the remaining studies, two examined the maternal risk factors 
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associated with the highest prevalence of positive drug screenings (Son et al., 2018; Wood et al., 
2014), and one study examined the effects of race on maternal targeted screening (Ellsworth et 
al., 2010). 
Most of the studies described the problem of increased substance abuse in pregnancy and 
the importance of proper screening to identify infants at-risk of withdrawal. Of those studies that 
compared hospital protocols and policies regarding maternal and infant drug screening, 
researchers found that a larger percentage of hospitals performed targeted screening as opposed 
to universal screening. Bogen et al. (2017) found that 90% of 76 hospitals from 34 states used 
risk-based screening compared to 3% that used universal screening. Miller et al. (2014) found 
that among 31 Maryland hospitals, 48% used targeted screening compared to 45% who used 
universal screening. Wood et al. (2017) found that in 69 Iowa hospitals, 90% used targeted 
screening and 0% used universal screening. Studies described maternal risk factors associated 
with targeted drug screening and included criteria such as a positive history of maternal drug 
screening at delivery or during pregnancy, a history of substance use disorder before pregnancy, 
limited or no prenatal care, maternal legal involvement, prior Child Protective Services (CPS) 
involvement, other offspring not in custody, placental abruption, preterm labor, maternal tobacco 
or alcohol use, HIV positive status, HbsAg positive status, Hepatitis C positive status, history of 
gonorrhea or syphilis, fetal demise, precipitous delivery, intra-uterine growth restriction (IUGR), 
unintended delivery outside of the hospital, and acting intoxicated during office visits or on 
admission to the hospital (Bogen et al., 2017; Buchi et al., 2013; Colby, 2017; Ellsworth et al., 
2010; Fonti et al., 2016; Miller et al., 2014; Murphy-Oikonen et al., 2010, Son et al., 2018; 
Wexelblatt et al., 2015, Wood et al., 2014). Although screening by risk factors can reduce cost, 
bias has been found to exist in how providers determine who should be screened. A study by 
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Ellsworth et al. (2010) identified 565 mothers that met criteria for targeted screening protocols, 
but only 20.7% of these women were actually screened. Of those screened appropriately, infants 
born to black mothers were three times more likely to be screened compared to white mothers. In 
assessing infants of mothers who did not meet any criteria for screening, infants of black mothers 
were four times more likely to be screened not having any risk factors. 
Researchers found that maternal drug testing not only revealed substance use during 
pregnancy, but showed women were not always honest in their self-reports of substance use due 
to fear of discrimination and legal retribution. Risk factors alone did not always determine 
whether a woman would have a positive result. When studying the prevalence of substance use 
by pregnant women in the office setting, Kreshak et al. (2016) and Schauberger et al. (2014) 
found that 13-30% of women tested positive for one or more substances in urine samples. Of 
those samples found to be positive, marijuana and opioids had the highest prevalence. Three 
studies examined the difference in maternal self-reports and risk factors in comparison to 
universal infant drug screening results (Lange et al., 2014; Murphy-Oikonen et al., 2010; 
Wexelblatt et al., 2015). Lange et al. (2014) found that detection of alcohol in meconium 
samples was four times higher than what was admitted in maternal self-reports, Murphy-Oikonen 
et al. (2010) found that mothers failed to admit drug use in 27% of positive urine samples and 
24% of positive meconium samples, Wexelblatt et al. (2015) found that 20% of opioid-positive 
urine drug screenings of infants occurred in mothers without standard risk factors.    
Of the four studies that examined the equivalence of meconium drug screening to 
umbilical cord screening, only one study found that umbilical cord screening was not as sensitive 
as meconium screening. Colby (2017) studied 217 subjects and found that 45 samples had a 
positive result in meconium and not umbilical cord and 17 samples had a positive result in 
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umbilical cord and not meconium. It was determined by this study that umbilical cord had a 
lower sensitivity but had >90% specificity in all but one drug class. Colby et al. (2019) used a 
sample of 501 infants and found that umbilical cord was more sensitive to amphetamines, 
barbiturates, and benzodiazepines than meconium and determined that umbilical cord and 
meconium was discordant. Labardee et al. (2017) studied 197 specimens and found that nine 
oxycodone and eight opiate results were found in meconium but not detected in umbilical cord 
and two methamphetamine results were found in umbilical cord but not detected in meconium. 
This study expressed the benefit of umbilical cord collection to nursing workflow and timing of 
collection. Meconium may take 24 hours or more for the infant to pass and collect, while 
umbilical cord is available immediately after delivery. This allows an easier collection by the 
nurse, less chance of missing a sample and allows the sample to be sent to the laboratory sooner. 
Palmer et al. (2017) sampled 2072 infants and found that umbilical cord and meconium testing 
did not differ significantly, and umbilical cord testing was better because it decreased missed 
collections, increased detection of iatrogenic medications provided during labor, decreased 
tampering of the sample, and eliminated insufficient sample volume. 
Agency Description 
This project took place on the Birthplace unit of Hardin Memorial Hospital in 
Elizabethtown, Ky. Hardin Memorial Hospital is a 300-bed hospital in Central Kentucky that 
includes six labor and delivery suites, fourteen postpartum couplet rooms, a newborn nursery, 
and a level II NICU with seven beds (Hardin Memorial Health, 2019). The Birthplace unit, 
which includes all these areas, is the ninth busiest newborn delivery unit in Kentucky and 
includes over 1,600 annual live births. The population of this study was all infants born between 
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September 1, 2015 and September 1, 2016 at Hardin Memorial Hospital who underwent 
umbilical cord drug screening as a result of a targeted drug screening policy.  
“The mission of Hardin Memorial Health is to exceed the physical, emotional, and 
spiritual needs of our patients, their families, our physicians, and our staff through the delivery of 
high-quality, comprehensive care to the people and communities we serve” (Hardin Memorial 
Health, 2019, para. 4). The vision of this organization is to be the leading choice of residents 
who live within the community as a result of relentless quality improvement. Hardin Memorial 
Hospital values the ability to succeed in this mission as well as be guided by this vision as a way 
to achieve respect, integrity, collaboration, excellence, and stewardship (Hardin Memorial 
Health, 2019). This DNP project supported the mission and vision of the organization by seeking 
to improve patient outcomes and quality of care in the newborn. With the only level II NICU in 
Central Kentucky, the main objective of this project was to assess the efficacy of a current 
targeted drug screening policy in order to better identify those infants who may be at-risk of 
NAS. 
The key stakeholders included the national, state, and local governments, behavioral 
health professionals, hospital social workers, child protective services (CPS), OB/GYNs, 
pediatricians, neonatologists, nurses, laboratories, and leadership. Government agencies use the 
project data to update information on NAS prevalence and recommendations for screening across 
the United States. Behavioral health professionals and social workers at the hospital offer 
resources and treatment to the mother. The social workers and CPS work together on each case 
where there is a positive screening result to assess the need for custody changes, home visits, or 
follow-up after discharge. OB/GYNs, pediatricians, neonatologists, and nurses are stakeholders 
related to their direct care of these patients. OB/GYNs provide information on maternal risk 
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factors and are updated on any positive results found so that they can provide appropriate care to 
the mother. Neonatologists and pediatricians screen, treat, and follow up with these infants. The 
laboratories are kept up to date on the timing and specificity and sensitivity of the results. Lastly, 
the project findings inform leadership about the need for permanent policy changes as well as to 
share this research with other delivery hospitals in order to provide recommendations for infant 
screening.  
The largest facilitator to the implementation of this project was the ease of access to the 
data, since this was a medical record review. The policy that this project was evaluating was one 
that was already in place and was being followed by the providers and nursing staff. There was 
no education or training needed and no informed consent needed, only approval through the 
research committee within the hospital and the IRB. Another facilitator was the support from 
leadership, providers, and nursing staff in making this project a success and determining which 
targeted screening criteria was the most accurate in identifying at-risk infants.  
The largest barrier to this project was availability of resources at this facility for a formal 
research project such as this. Although this hospital has a research committee, this often consists 
of quality improvement initiatives and does not include formal research where IRB approval is 
needed. Due to this, there were limited people within the facility who understood how the 
process worked or what steps were required to move forward. Many meetings had to be 
scheduled and questions asked from several leadership individuals to find out what was needed 
to advance this project forward. Another barrier to this project was the ability of IT to run the 
report that specifically isolated the population chosen. When having IT run the requested reports, 
this either included all infants born within this time period or a select number of infants that had 
samples missing. This created a lengthy process of reviewing every infant record over the one-
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year period to make sure no data was missed. Also, drug screen results had to be scanned into the 
medical record during the years chosen for this review, rather than being uploaded electronically, 
so some of the results were not readily available. Until the time when the result was 
automatically loaded into the medical record, many of the drug screening results had to be found 
through the umbilical cord drug screening laboratory. 
Project Design 
This project was a cross-sectional medical record review. This study involved collecting 
data on all infants born between September 1st, 2015 and September 1st, 2016 who met criteria 
for umbilical cord drug screening based on targeted screening criteria. This criteria included the 
following maternal risk factors: history of or current drug use, minimal prenatal care, precipitous 
labor, severe mood swings, unexplained sores on skin, abruptio placentae, inappropriate 
behavior, myocardial infarction, poor dentition, unexplained fetal demise, cerebrovascular 
accidents, late prenatal care, no prenatal care, repeated spontaneous abortions, or unexplained 
severe hypertension. These criteria also included the following infant risk factors: myocardial 
infarction in a healthy term newborn, urogenital anomalies, abnormal neurological behaviors, 
necrotizing enterocolitis in a healthy term newborn, cardiovascular accident in a healthy term 
newborn, or unexplained intrauterine growth restriction (IUGR), pediatrician (MD) order, 
preterm less than 36 weeks, and a prior history with CPS (see Appendix B). The following 
demographics were collected on each infant: gender, race/ethnicity, age of mother, and gestation 
at birth. The following admission, assessment, and discharge information was collected on each 
infant: need for NICU admission for NAS treatment with morphine therapy, average Finnegan 
score, highest Finnegan score, and length of stay. The following outcomes were measured for 
each infant: individual targeted screening criteria met for mother, individual targeted screening 
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met for infant, and the result of the drug screen (see Appendix C). Nominal data included the 
gender of the infant, the race of the infant, the infant and maternal drug screening criteria met, 
the result of the drug screening, and whether the infant was admitted to the NICU for treatment. 
Ordinal data included the gestation of the infant, length of stay, the highest Finnegan score, and 
the average Finnegan score. Interval data included the age of the mother. The population was 
found by having IT run a report on all infants born between these dates that had Finnegan 
scoring performed as well as all infants born within these dates that had an umbilical cord sent 
for drug screening. Data for this study was accessed using the electronic health record (EHR). 
Data analysis was quantitative and included frequency distributions for nominal data, and the 
means, standard deviations, and ranges for continuous variables. SPSS analysis was used to run a 
two-sample t-test to determine the significance of Finnegan scoring, and sensitivity and 
specificity was used to compare the number of positive and negative results to each risk factor. 
Project Methods 
 The method used for this study was a retrospective cross-sectional design that compared 
umbilical cord drug screening rates and results to risk factors associated with targeted drug 
screening criteria in order to determine which risk factors were the best predictor of a positive 
umbilical cord drug screening result. In order to measure this, the sensitivity and specificity were 
calculated for each of the risk factors (Table 3). In addition, the average and highest Finnegan 
scores were compared using a two-sample t-test to assess whether the difference in scores were 
significant when comparing those of a positive drug screen to those of a negative drug screen 
(Table 4). The mean, median, standard deviation, and ranges were collected for all continuous 
variables and the frequency and percentages were collected for each nominal variable (Tables 1 
and 2). 
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Procedures 
IRB Approval 
 An IRB application was submitted to the University of Kentucky’s IRB as well as Baptist 
Health Lexington’s IRB. Baptist Health Lexington is the IRB required for studies taking place at 
Hardin Memorial Hospital. Both applications were approved in September 2019.  
Sample 
 The sample size included 340 infants that met criteria for drug screening for one or more 
reasons listed in Appendix B. The positivity report listed in Table 5 shows that 341 umbilical 
cords were tested during the chosen timeframe, but only 340 infants were used for the sample 
size after performing the medical record review. The sample included all infants born between 
September 1st, 2015 to September 1st, 2016 who underwent umbilical cord drug screening as a 
result of the targeted drug screening policy. Infants born prior to September 1st, 2015 and after 
September 1st, 2016 and those infants that did not meet umbilical cord drug screening criteria 
were excluded from this study. 
Measures and Instruments 
 A medical record review was performed to collect the data on the sample and all 
information was found in the electronic health records of the infants. The nominal data collected 
included the gender of each infant, the race of each infant, whether the infant was admitted to the 
NICU for NAS treatment (i.e. morphine therapy), the results of the drug screening and whether 
the infant did or did not meet criteria for the following risk factors: history of drug use, minimal 
prenatal care, late prenatal care, no prenatal care, precipitous labor, severe mood swings, 
unexplained sores on skin, abruptio placentae, inappropriate behavior, myocardial infarction, 
poor dentition, unexplained fetal demise, cerebrovascular accident, repeated spontaneous 
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abortions, unexplained severe hypertension, myocardial infarction in healthy term newborn, 
urogenital anomalies, abnormal neuro behaviors, necrotizing enterocolitis in healthy term 
newborn, cardiovascular accident in health term newborn, unexplained intrauterine growth 
restriction (IUGR), preterm less than 36 weeks, previous history of CPS, and pediatrician (MD) 
order. The continuous variables measured were maternal age, gestation of the infant at birth, 
length of hospital stay, highest Finnegan score, and average Finnegan score (Appendix C). 
Implementation 
 In order to implement this project, a medical record review was performed. Since this 
project was a retrospective study that included a medical record review only, a waiver of 
informed consent was approved by the IRB. 
Results 
 The average maternal age for the 340 infants chosen for this project was 26 years old (SD 
= 5.71) and the average gestation at birth was 38.1 weeks (SD = 2.60). The mean for the average 
Finnegan score was 1.2 (SD = 1.39) and the mean for the highest Finnegan score was 3.5 (SD = 
3.23). The average length of stay for infants was 3.79 days (SD = 5.55), and the median number 
of days was 2 days (Table 1). The difference between the mean and median for length of stay is 
inconsistent with short stays for most infants, with longer stays for a small subset. If an infant 
was preterm or required morphine therapy in the NICU, the length of stay was as high as 50 
days. The median was chosen to provide a better reflection of the number of days most infants 
stayed in the hospital, as a least half of the infants stayed for two or fewer days.  
 The sample had a total of 164 (48.2%) males and 176 (51.8%) females. There was a total 
of 263 (77.6%) Caucasian infants, 55 (16.2%) African American infants, 15 (4.4%) Hispanic 
infants, 1 (0.3%) Native American infant, and 5 (1.5%) infants listed as “other”. Of the 340 
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infants in the sample, seven (2.1%) required morphine therapy for withdrawal treatment and 
were admitted to the NICU. When treating infants with morphine in the NICU for high Finnegan 
scores, the infant or mother must have tested positive for opiates. Out of the 341 umbilical cord 
samples reported in the positivity report, 40 (11.7%) were positive for opiates (Table 5). When 
considering that only opiate withdrawal infants received morphine therapy for NAS symptoms, a 
total of 17.5% of opiate-positive infants required treatment with morphine.   
 A total of 77 (22.6%) infants tested positive for the following substances: amphetamines, 
cocaine, opiates, cannabinoids, methadone, and benzodiazepines (Table 5). The maternal and 
infant risk factors used to drug screen all infants at this facility (Appendix B) showed 113 
(33.2%) mothers had a history of drug use (Table 2). Nearly 28% of the mothers had either 
minimal, late, or no prenatal care prior to delivery. Precipitous labor, placental abruption, and 
recurrent spontaneous abortions were noted criteria in 18.8% of the births. Inappropriate 
behavior or severe mood swings were identified as screening criteria in 5.6% of those who were 
tested. One in ten had poor maternal dentition or unexplained sores on the skin as criteria for 
screening. Infant findings were listed as criteria in 8.8% of those who were tested. Five percent 
of infants were drug screened based on a pediatrician or neonatologist order. Several of the 
criteria used for targeted screening were not found with any of those who were screened. Those 
risk factors not identified were maternal myocardial infarction, unexplained fetal demise, 
maternal cerebrovascular accident, unexplained severe maternal hypertension, myocardial 
infarction in a healthy term newborn, necrotizing enterocolitis in a healthy term newborn, and 
cerebrovascular accident in a healthy term newborn.  
Based on the number of risk factors found in the medical record, 16 (4.7%) infants had no 
risk factors, 275 (80.9%) infants had one risk factor, 43 (12.6%) had two identified risk factors, 
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and 6 (1.8%) infants had three risk factors present. A total of 291 (85.6%) infants had zero to one 
risk factors and 49 (14.4%) infants had more than one risk factor.  
 Two-sample t-tests were used to compare the average Finnegan scores and the highest 
Finnegan scores between those infants that tested positive and those that tested negative (Table 
4). The mean average Finnegan score for those infants that tested positive was 1.5 and the mean 
average Finnegan score for those that tested negative was 1.1. Based on the two-sample t-test 
performed, it was found that the difference in these averages was statistically significant. The 
mean highest Finnegan score for those infants that tested positive was 4.46 and the mean highest 
Finnegan score for those that tested negative was 3.22. Based on the two-sample t-test 
performed, it was found that the difference in the highest Finnegan scores was statistically 
significant (Table 4).  
 In the context of risk factor assessment, sensitivity is the percentage of women with a 
positive drug screen who were also positive for the corresponding risk factor. On the other hand, 
specificity is the percent of those with a negative drug screen who were also negative for the 
presence of the given risk factor. The risk factor with the highest sensitivity was maternal history 
of drug use, with a sensitivity of 51.9 (specificity 72.7) (Table 3). Minimal prenatal care had a 
sensitivity of 14.3 (specificity 85.9), late prenatal care had a sensitivity of 13.0 (specificity 87.8), 
precipitous labor had a sensitivity of 10.4 (specificity 90.8), poor dentition had a sensitivity of 
10.4 (specificity 89.4), and the remaining risk factors had sensitivities of less than 10%. The 
highest specificity was 100, which was found with cardiovascular accident in the mother and 
healthy term newborn, necrotizing enterocolitis in healthy term newborn, myocardial infarction 
in the mother and healthy term newborn, unexplained fetal demise, and maternal cerebrovascular 
accident; the sensitivity for all these risk factors was zero, as none of the mothers had any of 
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these risk factors. Given the number of possible risk factors, it was also considered that those 
infants with positive drug screens were more likely to have more than one risk factor. The 
sensitivity of having more than one risk factor was 20.8 and the specificity was 87.5 (Table 3). 
Discussion 
 The sensitivity of a screening test is the ability of a test to detect a true positive. It is the 
probability that someone with a positive drug screen will be flagged as high-risk using a given 
risk factor. When a test has a high sensitivity, there are very few false negative results (Maxim, 
Niebo, & Utell, 2014). The specificity of a screening test is the ability of a test to detect a true 
negative. It is the probability that those infants not exposed to drugs in utero will be negative on 
the identified risk factor as well. When a test has a high specificity, there are very few false 
positive results (Maxim et al., 2014). The best test would be one with 100% sensitivity and 
specificity because this would result in no error in the outcome, but this is not achievable in 
practice. Therefore, the most desirable test is one that has both high sensitivity and high 
specificity (Maxim et al., 2014). 
 When considering the risk factors used to screen infants for NAS, the highest sensitivity 
was 51.9% for history of drug use. Using the presence of having two or more risk factors as an 
evaluation tool was associated with only 20.8% sensitivity. The remainder of the risk factors 
were less than 15% sensitive. This sensitivity is far from 100% and is very low, which means 
there is a much higher risk of false negatives. In this context, a false negative would be a 
participant who had a positive drug screen but who was not positive for a given risk factor. The 
values for the specificities were much higher, with 20 out of the 24 risk factors being above 90%. 
Infants with multiple risk factors had a specificity of 87.5%. The lowest specificity was 72.7% 
for history of drug use, which means there is a relatively low risk of false positives with all of 
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these risk factors. A false positive in this study would have occurred if a participant had a 
negative drug screen but was positive for a particular risk factor. 
In using these data to identify whether risk factors are effective in evaluating risk of 
withdrawal, none of the risk factors were very sensitive in indicating positive drug screening 
results. In order to truly assess the number of positive results that are being missed, universal 
screening would have to be performed and compared between those who met risk factor 
screening and those who did not. Although it is more expensive to test every infant, it would 
allow a better determination of whether risk factors are efficient in finding all those infants at 
risk of NAS. It would also identify those risk factors most strongly linked to NAS outcomes. 
Another comparison considered differences in Finnegan scores between positive drug 
screening and negative drug screening. The Finnegan scoring tool is the most commonly used 
scoring system for evaluating infants with NAS (Pomar et al., 2017). Developed in 1975, it 
consists of 21 scored items or symptoms involving the central nervous system, the autonomic 
nervous system, and the gastrointestinal system. Higher scores are consistent with NAS 
(Appendix D). The recommendation for practice with the Finnegan tool is to consider further 
monitoring and initiation of pharmacological treatment if the infant has three consecutive scores 
of eight or more or two consecutive scores of 12 or more (Pomar et al., 2017).  
While performing the medical record review, it was noted that many infants with 
negative drug screens had high Finnegan scores. This could have been due to the infant 
withdrawing from other medications not tested on the 9-panel drug screen ordered for these 
screenings or it may have been due to the subjective nature of Finnegan scoring and the various 
people scoring the infant throughout the hospitalization. In performing a two-sample t-test on the 
average Finnegan scores and the highest Finnegan scores, it was found that the average Finnegan 
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score and highest Finnegan scores were significantly higher for the positive result group relative 
to those whose drug screens were negative. This suggests that, on average, there is a significant 
association between Finnegan scoring and drug screen results, even though some in the negative 
group had relatively high scores and some in the positive group had relatively low ones. 
Implications for Practice, Education, Policy, and Future Research 
 This project was started with advocating for universal drug screening. Due to the cost 
associated with screening all infants, the first step was proving that risk-based screening is not 
effective. By assessing the sensitivity and specificity of each risk factor, it was shown that these 
criteria are not very effective at determining those infants at risk of NAS. As stated in the 
literature review, risk-based screening may be based on bias or judgment and mothers are not 
always honest in their history (Terplan and Minkoff, 2017). This leads to infants being 
discharged without being screened for withdrawal symptoms, where they may reach the peak of 
withdrawal at home. By providing universal screening, there is a standardized process and no 
infant is missed and sent home without help.  
 Another area for improvement with NAS is increasing the hospital length of stay. 
Although infant’s met criteria for drug screening and the umbilical cord samples had not yet 
resulted, most infants were discharged after two days of birth. Most substances have a 
withdrawal onset of 24-72 hours and a total duration in the body of 2-30 days (Kocherlakota, 
2014). It is important to keep infants for the most appropriate amount of time to properly assess 
their readiness for discharge. While performing the medical record review, there were many 
infants that had high Finnegan scores throughout the hospital stay and were still discharged at 
two days of life. In a management plan recommended by Kocherlakota (2014), Finnegan scoring 
should begin within 24 hours of birth and occur every 3-4 hours. If scores remain consistently at 
 
27 
 
or below eight, the infant should continue to be observed for 3-5 more days before being 
discharged.  
The current policy at this facility states that infants who are exposed to opiates should be 
monitored for 4-5 days for signs of withdrawal. The hospital cost per day at this facility is 
$1054.00 for those infants outside of the NICU. With 252 infants being discharged at or before 2 
days of life (n=340), this would have resulted in an increase in cost of $265,608 - $796,824 if the 
length of stay was extended to 3-5 days. Although this would result in an increase in healthcare 
costs at this facility, this would decrease infant withdrawal at home and would allow social 
services to get involved before an infant is discharged home with a parent that tested positive for 
a substance. Not only would this prevent the negative physical effects of withdrawal but would 
also prevent the infant from discharging home to an environment that could place the infant in 
additional harm. If an infant presents to the hospital after discharge with severe NAS or 
nonaccidental trauma due to the social environment, this would result in an increase in healthcare 
costs overall as well as negative long term outcomes for the child. Since the umbilical cord 
processing time can take 3-6 days after birth, it is important to consider each infant’s Finnegan 
scores and the substances in which he or she is withdrawing from before deciding on a discharge 
date. 
 The future of this research involves replicating this study at other facilities with other risk 
factors to see if other criteria might be a better predictor of a positive drug screening. Each 
facility differs in their criteria, and there might be better efficacy with other risk factors. The 
current policy at this facility no longer includes infants less than 36 weeks and never included an 
MD order or previous history with CPS, although this was noted in some of the medical records. 
The sensitivity of preterm infants and MD order was 0% while history of CPS was 2.6%. 
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Perhaps preterm infants should not automatically be screened, and the MD should communicate 
other criteria for screening before placing this order. A previous history with CPS was found to 
be a risk factor at other facilities when performing the literature review and, although it was not 
very sensitive in this study, CPS often asks for a drug screening when reviewing these cases. 
This might be a risk factor that this facility should consider adding. If other facilities can 
replicate this research and find that their criteria are not very sensitive or specific, then universal 
screening may be the next step. 
 The future of this research is to compare universal screening to risk-based screening in 
order to determine how many infants are missed with risk-based screening alone. Although this 
would result in higher drug screening costs, all infants would be screened and scored for NAS in 
order to assess for signs of withdrawal and to provide treatment when necessary. By 
standardizing the approach to infant drug screening, no infants at risk of NAS would be missed. 
This would allow researchers to prove which type of screening is more effective and hospitals 
could begin to either standardize the risk criteria used or could begin providing universal 
screening. 
Limitations 
 One limitation of this study is the small sample size. Some risk criteria were not 
experienced by any participants in the study; a larger sample size would allow a better 
quantification of the sensitivity and specificity of each risk factor. In addition, not all risk factors 
were noted in the medical records of each infant. If a drug screening was performed after the 
infant was born, this was often not noted in the chart as to why. Without documentation of why 
an umbilical cord was sent for testing, there is no way to measure how effective the result was. 
During the time frame chosen for this review, the hospital also utilized a 9-panel umbilical cord 
 
29 
 
drug screening compared to the 13-panel drug screening used now. This could have resulted in 
negative drug screening results for those infants that were actually positive for these additional 
substances (oxycodone, meperidine, tramadol, and buprenorphine). Although the same infants 
would have been tested based on the risk factors associated, this might have resulted in more 
positive drug screenings. Some infants had multiple risk factors chosen, while others did not. 
Another limitation is not knowing whether more than one risk factor was not chosen because the 
infant did not have more than one risk factor or because only one option was chosen to trigger 
the infant drug screening.  
 One of the greatest limitations to this study was the lack of funding to support universal 
drug screening of all infants. Universal drug screening was supported by the pediatric and 
leadership team of the department, but the resources were not available to support this increase in 
drug screening cost. At this facility, the cost of a 13-panel umbilical cord drug screening is 
$177.00.  This cost is not billed to the patient, but is paid for by the hospital because this testing 
is performed at another laboratory outside of the hospital’s network. With a hospital average of 
1600 live births a year, this would result in over 1200 additional umbilical cord drug screenings. 
The increase in this cost would be over $220,000. In order to properly identify all those potential 
NAS infants that are being missed by risk-based screening, universal screening would need to be 
implemented and compared to risk-based screening. Without the resources to fund this project, 
there is no data to support the need for universal screening or the evidence to prove that it is 
more efficient in finding all infants at risk of NAS. 
Conclusion 
Early identification of infants at greatest risk of NAS can help determine those who 
would benefit from early intervention/treatment. The main goal of this project was to determine 
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if risk-based screening was efficient in determining a positive drug screening result. Without 
universal screening, more sensitive and specific risk-based screening is important in determining 
which infants are at greatest risk and need additional monitoring to assess for signs of 
withdrawal. Based on the statistical analysis, the risk factors associated with this project were not 
sensitive in finding positive infants. Maternal history of drug use was the only risk factor that 
had a high enough sensitivity to suggest significance. In order to be more efficient at scoring and 
monitoring infants with NAS, there must be a better process in place for identifying those that 
are at greatest risk. With more research on risk-based screening and more resources available to 
implement and study universal screening, there will continue to be advancements in identifying 
infants with NAS. With such significant side effects associated with withdrawal, it is important 
that this research continue and that infants be protected from suffering. In addition, 
understanding and identifying substance use in pregnancy can also provide more resources to the 
mother for help and sobriety. NAS involves family-centered care for both the infant and the 
mother, and proper screening is the first step in helping them in their journey to recovery.  
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Appendix A – Literature Review 
 
  
Type of Study Number of Studies Authors 
Systemic Literature Review 1 Lange, Shield, Koren, Rehm, & Popova, 2014 
Cohort Analysis 10 Colby, 2017; Colby, Adams, Morad, Presley, & 
Patrick, 2019; Ellsworth, Stevens, & D’Angio, 2010; 
Kreshak et al., 2016; Murphy-Oikonen, Montelpare, 
Southon, Bertoldo, & Persichino, 2010; Palmer, 
Wood, & Krasowski, 2017; Schauberger, Newbury, 
Colburn, & Al-Hamadani, 2014; Son, Guiahi, 
Heyborne, 2018; Wexelblatt et al., 2015; Wood et al., 
2014 
Comparison Study 1 Labardee et al., 2017 
Cross-sectional Study 1 Buchi, Suarez, & Varner, 2013 
Survey 3 Bogen, Whalen, Kair, Vining, & King, 2017; Miller, 
Lanham, Welsh, Ramanadhan, & Terplan, 2014; 
Wood, Smith, & Krasowski, 2017 
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Appendix B – Drug Screening Criteria 
 
Targeted Drug Screening Criteria at Hardin Memorial Hospital 
Maternal Considerations Infant Considerations 
History or Current Drug Abuse Myocardial Infarction in Healthy Term Newborn 
Minimal Prenatal Care Urogenital Anomalies  
Precipitous Labor Abnormal Neuro Behaviors 
Severe Mood Swings Necrotizing Enterocolitis in Healthy Term Newborn 
Unexplained Sores on Skin Cardiovascular Accident in Healthy Term Newborn 
Abruptio Placentae Unexplained Intrauterine Growth Restriction (IUGR) 
Inappropriate Behavior Preterm Less than 36 Weeks 
Myocardial Infarction Pediatrician (MD) order 
Poor Dentition   
Unexplained Fetal Demise   
Cerebrovascular Accidents   
Late Prenatal Care   
No Prenatal Care   
Repeated Spontaneous Abortions   
Unexplained Severe Hypertension   
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Appendix C – Data Collection 
 
Measures Description Level of Measurement Data Source 
Demographics 
Gender of Infant Male vs Female Nominal Electronic Health 
Records 
Race/Ethnicity of Infant Caucasian, African American, 
Hispanic, Native American, Other 
Nominal/Categorical Electronic Health 
Records 
Maternal Age Age in years Interval/Ratio Electronic Health 
Records 
Gestation  Gestation by weeks Ordinal Electronic Health 
Records 
 
Admission, Assessment, and Discharge Information 
  
Need for NICU admission Was infant admitted to the NICU 
for NAS treatment (i.e. morphine 
therapy)? 
Nominal Electronic Health 
Records 
Finnegan Score Highest Finnegan Score Ordinal Electronic Health 
Records 
Finnegan Score Average Finnegan Score Ordinal Electronic Health 
Records 
Length of Stay for Infants Average Length of Stay in Days Ordinal Electronic Health 
Records 
 
Outcomes 
  
History of Drug Use Yes/No  Nominal Electronic Health 
Records 
Minimal Prenatal Care Yes/No Nominal Electronic Health 
Records 
Late Prenatal Care Yes/No Nominal Electronic Health 
Records 
No Prenatal Care Yes/No Nominal Electronic Health 
Records 
Precipitous Labor Yes/No Nominal Electronic Health 
Records 
Severe Mood Swings Yes/No Nominal Electronic Health 
Records 
Unexplained Sores on Skin Yes/No Nominal Electronic Health 
Records 
Abruptio Placentae Yes/No Nominal Electronic Health 
Records 
Inappropriate Behavior Yes/No Nominal Electronic Health 
Records 
Myocardial Infarction Yes/No Nominal Electronic Health 
Records 
Poor Dentition Yes/No Nominal Electronic Health 
Records 
Unexplained Fetal Demise Yes/No Nominal Electronic Health 
Records 
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Cerebrovascular Accident Yes/No Nominal Electronic Health 
Records 
Repeated Spontaneous Abortions Yes/No Nominal Electronic Health 
Records 
Unexplained Severe Hypertension Yes/No Nominal Electronic Health 
Records 
Myocardial Infarction in Healthy Term 
Newborn 
Yes/No Nominal Electronic Health 
Records 
Urogenital Anomalies Yes/No Nominal Electronic Health 
Records 
Abnormal Neuro Behaviors Yes/No Nominal Electronic Health 
Records 
Necrotizing Enterocolitis in Healthy 
Term Newborn 
Yes/No Nominal Electronic Health 
Records 
Cardiovascular Accident in Healthy Term 
Newborn 
Yes/No Nominal Electronic Health 
Records 
Unexplained Intrauterine Growth 
Restriction (IUGR) 
Yes/No Nominal Electronic Health 
Records 
Preterm Less than 36 Weeks Yes/No Nominal Electronic Health 
Records 
Previous History with CPS Yes/No Nominal Electronic Health 
Records 
Pediatrician (MD) Order Yes/No Nominal Electronic Health 
Records 
Result of Drug Screen Positive/Negative Nominal Electronic Health 
Record 
 
 
 
 
 
 
 
 
39 
 
Appendix D – Finnegan Scoring 
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Table 1.  Means, medians, standard deviations and ranges for selected continuous variables: (N =340). 
Variable Mean Median Standard 
Deviation 
Actual Range 
Maternal Age 26.07 25.00 5.71 15 – 44  
Gestation at Birth 38.14 39.00 2.60 20.1 – 42.0  
Average Finnegan Score 1.20 0.75 1.39 0 – 9.43  
Highest Finnegan Score 3.50 3.00 3.23 0 – 17  
Length of Hospital Stay 3.79 2.00 5.55 0 – 50  
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Table 2. Frequency distributions for selected categorical variables (N=340)    
Variable Frequency Percent (%) 
Gender 
     Male 
     Female 
 
164 
176 
 
48.2 
51.8 
Race 
     Caucasian 
     African American 
     Hispanic 
     Native American 
     Other   
 
 263 
 55 
 15 
 1 
 5 
 
77.6 
16.2 
4.4 
0.3 
1.5 
Need for NICU Admission for NAS Treatment? 
     Yes 
     No 
 
7 
333 
 
2.1 
97.9 
Result of Drug Screen 
     Positive 
     Negative       
 
77 
263 
 
22.6 
77.4 
History of Drug Use 
     Yes 
     No 
 
113 
227 
 
33.2 
66.8 
Minimal Prenatal Care 
     Yes 
     No 
 
48 
292 
 
14.1 
85.9 
Late Prenatal Care 
     Yes 
     No 
 
42 
298 
 
12.4 
87.6 
No Prenatal Care 
     Yes 
     No 
 
4 
336 
 
1.2 
98.8 
Precipitous Labor 
     Yes 
     No 
 
32 
307 
 
9.4 
90.6 
Severe Mood Swings 
     Yes 
     No 
 
2 
338 
 
0.6 
99.4 
Unexplained Sores on Skin 
     Yes 
     No 
 
7 
333 
 
2.1 
97.9 
Abruptio Placentae 
     Yes 
     No 
 
9 
331 
 
2.6 
97.4 
Inappropriate Behavior 
     Yes 
     No 
 
17 
323 
 
5.0 
95.0 
Myocardial Infarction in Mother 
     Yes 
     No 
 
0 
340 
 
0 
100.0 
Poor Dentition 
     Yes 
     No 
 
36 
304 
 
10.6 
89.4 
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Unexplained Fetal Demise 
     Yes 
     No 
 
0 
340 
 
0 
100.0 
Cerebrovascular Accident in Mother 
     Yes 
     No 
 
0 
340 
 
0 
100.0 
Repeated Spontaneous Abortions 
     Yes 
     No 
 
23 
317 
 
6.8 
93.2 
Unexplained Severe Hypertension 
     Yes 
     No 
 
0 
340 
 
0 
100.0 
Myocardial Infarction in Healthy Term Newborn 
     Yes 
     No 
 
0 
340 
 
0 
100.0 
Urogenital Anomalies 
     Yes 
     No 
 
1 
339 
 
0.3 
99.7 
Abnormal Neuro Behaviors 
     Yes 
     No 
 
11 
329 
 
3.2 
96.8 
Necrotizing Enterocolitis in Health Term Newborn 
     Yes 
     No 
 
0 
340 
 
0 
100.0 
Cerebrovascular Accident in Healthy Term Newborn 
     Yes 
     No 
 
0 
340 
 
0 
100.0 
Unexplained Intrauterine Growth Restriction 
     Yes 
     No 
 
7 
332 
 
2.1 
97.6 
Preterm Less than 36 Weeks 
     Yes 
     No 
 
4 
336 
 
1.2 
98.8 
Pediatrician (MD) Order 
     Yes 
     No 
 
16 
324 
 
4.7 
95.3 
Number of Risk Factors 
     0 
    1 
    2 
    3 
 
16 
275 
43 
6 
 
4.7 
80.9 
12.6 
1.8 
Multiple Risk Factors 
     0-1 
     >1 
 
291 
49 
 
85.6 
14.4 
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Table 3. Sensitivity and specificity for each risk factor relative to outcome of postnatal drug screen (N = 340). 
Risk Factor in Mother Sensitivity (%) Specificity (%) 
History of drug use 51.9 72.7 
Minimal Prenatal Care 14.3 85.9 
Late Prenatal Care 13.0 87.8 
No Prenatal Care 2.6 99.2 
Precipitous Labor 10.4 90.8 
Severe Mood Swings 1.3 99.6 
Unexplained Sores on Skin 0 97.3 
Abruptio Placentae 1.3 97.0 
Inappropriate Behavior 2.6 94.3 
Myocardial Infarction in Mother 0 100.0 
Poor Dentition 10.4 89.4 
Unexplained Fetal Demise 0 100.0 
Cerebrovascular Accident in Mother 0 100.0 
Repeated Spontaneous Abortions 5.2 92.8 
Unexplained Severe Hypertension 0 100.0 
   
Risk Factor in Infant Sensitivity (%) Specificity (%) 
Myocardial Infarction in Healthy Term Newborn 0 100.0 
Urogenital Anomalies 0 99.6 
Abnormal Neuro Behaviors 1.3 96.2 
Necrotizing Enterocolitis in Health Term Newborn 0 100.0 
Cardiovascular Accident in Healthy Term Newborn 0 100.0 
Unexplained Intrauterine Growth Restriction 1.3 97.7 
Preterm Less Than 36 Weeks 0.0 98.5 
Previous History with CPS 2.6 98.1 
Pediatrician (MD) Order 0.0 93.9 
   
Multiple Risk Factors in Mother and/or Infant Sensitivity (%) Specificity (%) 
     >1 Risk Factors 20.8 87.5 
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Table 4. Comparison of Average and Highest Finnegan Scores for Positive and Negative Drug Screening Results 
 Mean Standard Deviation |t| p Significant? 
Average Finnegan Score 
     Negative Result 
     Positive Result    
 
1.1 
1.5 
 
1.27 
1.70 
 
2.0 
 
.049 
 
Yes 
Highest Finnegan Score 
     Negative Result 
     Positive Result 
 
3.22 
4.46 
 
2.94 
3.93 
 
2.6 
 
.012 
 
Yes 
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Table 5. Positivity report for umbilical cord drug screenings performed from 9/1/15 – 9/1/16. 
